Insulet (NASDAQ:PODD) Stock Unloaded by Rep. Gilbert Ray Cisneros, Jr.

Representative Gilbert Ray Cisneros, Jr. (Democratic-California) recently sold shares of Insulet Corporation (NASDAQ:PODD). In a filing disclosed on October 12th, the Representative disclosed that they had sold between $1,001 and $15,000 in Insulet stock on September 18th. The trade occurred in the Representative’s “150 MAIN STREET TRUST > BANK OF AMERICA” account.

Representative Gilbert Ray Cisneros, Jr. also recently made the following trade(s):

• Purchased $15,001 – $50,000 in shares of Benchmark Electronics (NYSE:BHE) on 10/1/2026.
• Sold $1,001 – $15,000 in shares of Oxford Industries (NYSE:OXM) on 9/29/2026.
• Sold $1,001 – $15,000 in shares of Semtech (NASDAQ:SMTC) on 9/29/2026.
• Sold $15,001 – $50,000 in shares of ITT (NYSE:ITT) on 9/29/2026.
• Sold $1,001 – $15,000 in shares of BridgeBio Pharma (NASDAQ:BBIO) on 9/29/2026.
• Purchased $1,001 – $15,000 in shares of Tandem Diabetes Care (NASDAQ:TNDM) on 9/29/2026.
• Purchased $1,001 – $15,000 in shares of Cytokinetics (NASDAQ:CYTK) on 9/29/2026.
• Purchased $1,001 – $15,000 in shares of Ultragenyx Pharmaceutical (NASDAQ:RARE) on 9/29/2026.
• Purchased $1,001 – $15,000 in shares of YETI (NYSE:YETI) on 9/29/2026.
• Sold $1,001 – $15,000 in shares of AtriCure (NASDAQ:ATRC) on 9/29/2026.

Insulet Stock Down 1.2%

Shares of NASDAQ:PODD opened at $138.13 on Wednesday. The business has a 50-day moving average price of $140.56 and a 200 day moving average price of $158.02. The company has a current ratio of 2.48, a quick ratio of 1.83 and a debt-to-equity ratio of 0.65. The company has a market capitalization of $9.58 billion, a price-to-earnings ratio of 25.82, a PEG ratio of 1.10 and a beta of 1.11. Insulet Corporation has a 12-month low of $126.40 and a 12-month high of $354.88.

Insulet (NASDAQ:PODD) last issued its quarterly earnings data on Wednesday, August 5th. The medical instruments supplier reported $1.66 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.47 by $0.19. Insulet had a net margin of 12.29% and a return on equity of 29.29%. The firm had revenue of $801.70 million for the quarter, compared to analyst estimates of $787.39 million. During the same period in the previous year, the firm earned $1.17 EPS. Insulet’s revenue was up 23.5% on a year-over-year basis. Insulet has set its FY 2026 guidance at 6.460- EPS. Sell-side analysts expect that Insulet Corporation will post 6.51 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of brokerages have weighed in on PODD. TD Cowen dropped their price target on shares of Insulet from $294.00 to $144.00 and set a “hold” rating for the company in a research report on Thursday, August 6th. Jefferies Financial Group reduced their price target on shares of Insulet from $275.00 to $190.00 and set a “buy” rating on the stock in a research note on Monday. Barclays upgraded shares of Insulet to a “hold” rating in a report on Wednesday, October 7th. Sanford C. Bernstein decreased their price objective on shares of Insulet from $200.00 to $175.00 and set an “outperform” rating on the stock in a report on Thursday, August 6th. Finally, Deutsche Bank Aktiengesellschaft began coverage on shares of Insulet in a research report on Tuesday, June 23rd. They set a “buy” rating and a $190.00 price objective for the company. Thirteen analysts have rated the stock with a Buy rating, twelve have assigned a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, the stock presently has an average rating of “Hold” and a consensus target price of $186.68.

Hedge Funds Weigh In On Insulet

A number of institutional investors and hedge funds have recently made changes to their positions in the stock. MV Capital Management Inc. acquired a new stake in shares of Insulet in the 4th quarter valued at about $29,000. Elevation Wealth Partners LLC increased its position in Insulet by 115.6% during the third quarter. Elevation Wealth Partners LLC now owns 194 shares of the medical instruments supplier’s stock worth $25,000 after buying an additional 104 shares during the period. Sound Income Strategies LLC increased its position in Insulet by 4,620.0% during the first quarter. Sound Income Strategies LLC now owns 236 shares of the medical instruments supplier’s stock worth $49,000 after buying an additional 231 shares during the period. State of Wyoming increased its position in Insulet by 34.6% during the first quarter. State of Wyoming now owns 284 shares of the medical instruments supplier’s stock worth $60,000 after buying an additional 73 shares during the period. Finally, Continuum Advisory LLC purchased a new stake in Insulet in the second quarter valued at approximately $46,000.

About Representative Cisneros

Gil Cisneros (Democratic Party) is a member of the U.S. House, representing California’s 31st Congressional District. He assumed office on January 3, 2025. His current term ends on January 3, 2027.

Cisneros (Democratic Party) is running for re-election to the U.S. House to represent California’s 31st Congressional District. He declared candidacy for the 2026 election.

Gil Cisneros served in the U.S. Navy as a supply officer from 1994 to 2004. Cisneros earned a bachelor’s degree in political science from George Washington University in 1994, a master’s in business administration from Regis University in 2002, and a master’s degree in urban education policy from Brown University in 2015. His career experience includes working as a logistics manager for Frito-Lay. In 2010, Cisneros won the lottery and became involved in activism and philanthropy, founding a scholarship program for local high school students. In 2021, President Joe Biden (D) appointed Cisneros as under secretary of defense for personnel and readiness.

About Insulet

Insulet Corporation is a medical device company that develops, manufactures and markets wearable insulin delivery systems for people with diabetes. The company is best known for its Omnipod platform, which is designed to provide insulin delivery without the tubing traditionally associated with conventional insulin pumps.

Insulet’s product portfolio includes the Omnipod 5 Automated Insulin Delivery System, a tubeless, wearable system that integrates with continuous glucose monitoring technology to automate insulin delivery, as well as the Omnipod DASH system.